Amivantamab + Docetaxel for Non-Small Cell Lung Cancer

(swalloWTail Trial)

Not currently recruiting at 17 trial locations

Overseen By Study Contact

Age: 18+

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Janssen Research & Development, LLC

Must not be taking: Corticosteroids, Paclitaxel

Disqualifiers: Oncogenic mutations, ILD, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 42

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new combination of two drugs, amivantamab (a monoclonal antibody) and docetaxel (a chemotherapy drug), to treat non-small cell lung cancer (NSCLC) that has metastasized. The main goal is to determine the optimal dose and assess the effectiveness of this combination in patients whose cancer has progressed despite previous treatments. The trial seeks participants with NSCLC who have not benefited from platinum-based chemotherapy and immune checkpoint inhibitor treatments. Candidates with NSCLC and no specific gene mutations (such as EGFR or ALK) are eligible if they are stable and have at least one measurable tumor. As a Phase 1, Phase 2 trial, this research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that amivantamab treats a type of lung cancer with specific gene changes, indicating prior testing in people. It is generally well-tolerated, but like any treatment, it can cause side effects, such as skin rash and swelling.

Docetaxel, a chemotherapy drug used for many years, is known to cause side effects like hair loss and low blood cell counts, so monitoring these effects during treatment is important.

This study uses amivantamab and docetaxel together, which might lead to different side effects or benefits. The study aims to find the safest dose for this combination. Early studies focus on identifying a dose that works well while minimizing side effects. Researchers closely monitor for any negative reactions, and participants undergo regular checks to ensure their safety. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about combining amivantamab with docetaxel for treating non-small cell lung cancer because it offers a novel approach compared to standard treatments like surgery, radiation, chemotherapy, and targeted therapies. Amivantamab is an innovative monoclonal antibody that uniquely targets both the EGFR and MET pathways, which are key drivers of cancer cell growth and survival. This dual-targeting mechanism could potentially overcome resistance seen in other treatments. By pairing amivantamab with docetaxel, a well-established chemotherapy drug, there's hope for enhanced effectiveness, offering patients a new avenue for combating this challenging cancer type.

What evidence suggests that the amivantamab and docetaxel combination could be an effective treatment for non-small cell lung cancer?

Research has shown that amivantamab can fight certain cancer cells by targeting proteins called EGFR and MET, which help these cells grow. One study found that amivantamab caused tumors to shrink in 82% of patients, demonstrating its potential. Docetaxel, a well-known chemotherapy drug, has treated various cancers for many years. This trial investigates the combination of amivantamab and docetaxel to determine if it is more effective for treating non-small cell lung cancer (NSCLC) than using either one alone. Early results suggest that this combination could offer new hope for NSCLC patients with limited treatment options. ^{1 2 4 6 7}

Who Is on the Research Team?

Janssen Research &Development, LLC Clinical Trial

Principal Investigator

Janssen Research & Development, LLC

Are You a Good Fit for This Trial?

This trial is for people with metastatic non-small cell lung cancer who have seen their disease progress after platinum-based chemotherapy and immune checkpoint inhibitor treatment. Participants should not have oncogenic driver mutations.

Inclusion Criteria

I have at least one tumor that can be measured and hasn't been treated with radiation.

I had another type of cancer, but it won't affect this study's treatment.

I am fully active or can carry out light work.

Exclusion Criteria

I have or had cancer spread to the lining of the brain and spine or untreated spinal cord compression.

My cancer has specific genetic changes (like EGFR, MET).

Medical history of (non-infectious) ILD/pneumonitis, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening- Participant has history of any significant drug allergy (such as anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia) or has known allergies, hypersensitivity, or intolerance to: a. amivantamab or amivantamab excipients (refer to the amivantamab IB); b.docetaxel, docetaxel excipients or to other drugs formulated with polysorbate and paclitaxel

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase 1: Combination Dose Selection

Participants receive amivantamab and docetaxel to determine the recommended Phase 2 combination dose (RP2CD). Doses are adjusted based on dose limiting toxicities.

Up to 21 days

Multiple visits per 21-day cycle

Phase 2: Dose Expansion

Participants receive amivantamab and docetaxel at the RP2CD to evaluate antitumor effects. Treatment continues until disease progression or unacceptable toxicity.

Up to 1 year 4 months

Regular visits per 21-day cycle

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Amivantamab
• Docetaxel

Trial Overview The study is testing a combination of two drugs, Amivantamab and Docetaxel, to determine the best dose for Phase 2 trials and to assess how well this combo works in treating NSCLC at that dose.

How Is the Trial Designed?

Group I: Phase 2 (Dose Expansion) Experimental Treatment 2 Interventions

Participants will receive amivantamab in combination with docetaxel in 2 cohorts (Cohort A \[adenocarcinoma\] and Cohort B \[squamous\]) at the RP2CD determined in Phase 1. Participants will continue study treatment until disease progression, unacceptable toxicity, or until another criterion for discontinuation of study treatment is met.

Group II: Phase 1 (Combination Dose Selection) Experimental Treatment 2 Interventions

Participants will receive amivantamab intravenous (IV) infusion administered based on body weight from Cycle 1 Day 1, Day 2, and subsequent doses on Days 8 and 15, and then on Day 1 of each 21-day treatment cycle. Docetaxel will be administered on Day 2 of Cycle 1 (before Day 2 amivantamab infusion) and then on Day 1 of each 21-day treatment cycle, thereafter. Doses will be escalated or de-escalated based on the dose limiting toxicities (DLTs) and the recommended Phase 2 combination dose (RP2CD) will be determined. Participants will continue study treatment until disease progression, unacceptable toxicity, or until another criterion for discontinuation of study treatment is met.

Amivantamab is already approved in United States, European Union for the following indications:

Approved in United States as Rybrevant for:

• Locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations
• Locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations

Approved in European Union as Rybrevant for:

• Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations
• Locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations

Who Is Running the Clinical Trial?

Janssen Research & Development, LLC

Lead Sponsor

Trials

1,022

Recruited

6,408,000+

Joaquin Duato

Janssen Research & Development, LLC

Chief Executive Officer since 2022

MBA from ESADE, Master of International Management from Thunderbird School of Global Management

Dr. Jijo James, MD

Janssen Research & Development, LLC

Chief Medical Officer since 2014

MD from St. Johns Medical College, MPH from Columbia University

Published Research Related to This Trial

Docetaxel has been established as the preferred treatment for advanced non-small cell lung cancer that does not respond to initial chemotherapy, based on the results of two recent trials.

Ongoing trials are exploring the use of docetaxel not only as a primary treatment but also in combination with radiation therapy, indicating its potential versatility in cancer treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: An international update. Kris, MG., Manegold, C.[2019]

In a phase 2 trial involving 40 chemotherapy-naïve patients with advanced nonsquamous NSCLC, the combination of carboplatin, docetaxel, and bevacizumab resulted in a median progression-free survival of 7.9 months and a median overall survival of 16.5 months, indicating its effectiveness as a front-line treatment.

The treatment was generally tolerable, with a high disease control rate of 95%, although some patients experienced significant adverse events, including infections and bleeding, highlighting the need for careful monitoring during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. William, WN., Kies, MS., Fossella, FV., et al.[2018]

Docetaxel, when combined with other agents like cisplatin and gemcitabine, shows promising response rates (up to 53%) and median survival times (8 to 13 months) in patients with non-small-cell lung cancer, based on multiple phase I and II trials.

The combinations of docetaxel with other treatments have manageable adverse effects, making them a viable option for patients, with ongoing phase III trials to further evaluate their effectiveness in first-line treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program. Ornstein, DL., Nervi, AM., Rigas, JR.[2022]

In a study of 30 patients with previously treated non-squamous non-small cell lung cancer, the addition of bevacizumab to docetaxel or pemetrexed resulted in a median progression-free survival of 5.0 months and an overall survival of 15.8 months, indicating potential efficacy in this salvage treatment setting.

While the treatment was generally well tolerated, there was a notable 10% incidence of osteonecrosis of the jaw, highlighting the need for careful monitoring of this side effect.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study. Yamaguchi, K., Masuda, T., Fujitaka, K., et al.[2019]

In a phase I trial involving 27 patients with advanced refractory cancer, the combination of sorafenib and docetaxel showed significant alterations in the pharmacokinetics of docetaxel, with increases in both the area under the concentration-time curve (AUC) and maximum concentration (Cmax).

The treatment was associated with a high incidence of adverse events, particularly dermatologic issues, leading to dose adjustments; however, 11% of patients experienced partial responses and 52% had stable disease, suggesting some efficacy in this challenging patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Awada, A., Hendlisz, A., Christensen, O., et al.[2018]

In a study of 39 chemotherapy-naïve patients with advanced non-small cell lung cancer, the combination of irinotecan and docetaxel resulted in a partial response in 23% of patients, with a median survival time of 10.8 months and a 1-year survival rate of 42.2%.

The treatment was associated with manageable side effects, including grade 4 neutropenia in 10.3% of patients and grade 3 or 4 diarrhea in 23.1%, indicating that this non-platinum-based regimen could be a viable option for patients who cannot tolerate traditional platinum-based therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study. Ziotopoulos, P., Androulakis, N., Mylonaki, E., et al.[2018]

In a phase II study involving 160 Japanese patients with non-small cell lung cancer (NSCLC), the combination of ramucirumab and docetaxel significantly prolonged progression-free survival (PFS) compared to placebo-docetaxel, with a median PFS of 5.22 months versus 4.21 months.

While overall survival rates were similar between the two groups, the ramucirumab-docetaxel combination showed a higher objective response rate (28.9% vs 18.5%) and a higher disease control rate (78.9% vs 70.4%), although it was associated with a higher incidence of febrile neutropenia (34.2% vs 19.8%).

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Yoh, K., Hosomi, Y., Kasahara, K., et al.[2023]

Docetaxel is an effective treatment for non-small cell lung cancer (NSCLC), showing comparable efficacy to newer platinum-based therapies in advanced stages, and has been approved for use in this context.

Clinical trials are ongoing to explore the best ways to combine docetaxel with other treatments, such as thoracic radiotherapy and molecularly targeted agents, to enhance its effectiveness in various stages of NSCLC.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Docetaxel in non-small cell lung cancer: a review. Davies, AM., Lara, PN., Mack, PC., et al.[2019]

This phase 2 study aims to evaluate the safety and preliminary efficacy of a combination treatment of docetaxel, ramucirumab, and pembrolizumab in 41 patients with metastatic or recurrent non-small-cell lung cancer (NSCLC) who have progressed after standard therapies.

The primary goal is to assess the 6-month progression-free survival (PFS) rate, which could provide insights into new treatment strategies for NSCLC, especially for patients who have not responded to previous therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade. Osta, BE., Carlisle, J., Steuer, C., et al.[2023]

In a subgroup analysis of 89 East Asian patients with stage IV non-small cell lung cancer, the combination of docetaxel and ramucirumab showed improved overall survival (15.44 months) and progression-free survival (4.88 months) compared to docetaxel plus placebo, aligning with results from the overall study of 1,253 patients.

Reducing the starting dose of docetaxel from 75 mg/m2 to 60 mg/m2 in East Asian patients led to improved safety outcomes, with a lower incidence of neutropenia and febrile neutropenia, highlighting the importance of dose adjustments in this population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL). Park, K., Kim, JH., Cho, EK., et al.[2023]

Docetaxel is an effective treatment for advanced non-small cell lung cancer (NSCLC), showing survival benefits in both first- and second-line therapy, and is comparable or superior to other platinum-based chemotherapy options.

The drug has a manageable toxicity profile and has shown promising results when combined with novel targeted agents in Phase II studies, indicating its versatility in treatment regimens.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Docetaxel in advanced non-small cell lung cancer. Wakelee, H., Ramalingam, S., Belani, CP.[2018]

In a study of 130 patients with recurrent non-small-cell lung cancer (NSCLC), combining docetaxel with irinotecan did not significantly improve overall survival or response rates compared to docetaxel alone, but it did prolong the time to tumor progression (5.6 months vs. 4.8 months).

While the combination treatment had similar rates of severe neutropenia and anemia as docetaxel alone, it was associated with higher rates of thrombocytopenia and diarrhea, indicating a need to consider potential side effects when choosing treatment options.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Pectasides, D., Pectasides, M., Farmakis, D., et al.[2020]

In a study of 27 patients with inoperable non-small-cell lung cancer (NSCLC) who had previously received platinum-based chemotherapy, docetaxel showed a partial response rate of 24%, indicating its effectiveness as a treatment option.

The main side effect observed was severe neutropenia in 75% of patients, highlighting the need for careful monitoring of blood cell counts during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology]. Robinet, G., Thomas, P., Pérol, M., et al.[2018]

Docetaxel has been established as the preferred treatment for advanced non-small cell lung cancer that does not respond to initial chemotherapy, based on the results of two recent trials.

Ongoing trials are exploring the use of docetaxel not only as a primary treatment but also in combination with radiation therapy, indicating its potential versatility in cancer treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update. Kris, MG., Manegold, C.[2019]

In a Phase II study involving 46 patients with non-small cell lung cancer (NSCLC), the combination of docetaxel and irinotecan showed some efficacy, with 11% of patients achieving a confirmed response, but it was associated with significant toxicity.

The most common severe side effects included neutropenia (67%), diarrhea (28%), and fatigue (20%), leading to the conclusion that while the treatment has some activity, it is not recommended over single-agent therapies due to the high risk of adverse events.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer. Molina, JR., Nikcevich, D., Hillman, S., et al.[2018]

Citations

1. isrctn.com isrctn.com/ISRCTN23584582

A Phase 1/2 Study Evaluating the ... Amivantamab binds to EGFR & MET and turns them off, which may slow the growth of cancer cells. Docetaxel is an approved anti-cancer treatment, used for ...

2. clinicaltrials.gov clinicaltrials.gov/study/NCT06532032

NCT06532032 | A Study of Combination Therapy With ... The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in ...

3. trialx.com trialx.com/clinical-trials/listings/293807/a-study-of-combination-therapy-with-amivantamab-and-docetaxel-in-participants-with-metastatic-non-small-cell-lung-cancer/

A Study of Combination Therapy With Amivantamab and ... The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy ...

4. jnj.com jnj.com/media-center/press-releases/subcutaneous-amivantamab-delivers-promising-45-percent-overall-response-rate-with-median-duration-of-7-2-months-in-recurrent-or-metastatic-head-and-neck-cancer

Subcutaneous amivantamab delivers promising 45 percent ... Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study ...

5. ncbi.nlm.nih.gov ncbi.nlm.nih.gov/books/NBK594393/

Clinical Review - Amivantamab (Rybrevant) - NCBI - NIH Amivantamab for the treatment of adult patients with advanced non-small cell lung cancer with activating epidermal growth factor exon 20 insertion mutations ...

6. investor.jnj.com investor.jnj.com/investor-news/news-details/2025/Data-published-in-The-New-England-Journal-of-Medicine-demonstrate-RYBREVANT-amivantamab-vmjw-plus-LAZCLUZE-lazertinib-is-re-setting-survival-expectations-in-first-line-EGFR-mutated-lung-cancer/default.aspx

News Details - JNJ Investor Relations Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, ...

7. jto.org jto.org/article/S1556-0864(24)02550-4/fulltext

Amivantamab Plus Lazertinib in Patients With EGFR ... Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer.